A Single-center, Randomized, Double-blind, Placebo-controlled, Three-way Crossover Phase I Study to Investigate the Effect on the QTc Interval of a Single Dose of AZD6094 (600 mg) Compared With Placebo, Using Open-label Moxifloxacin (Avelox) as a Positive Control, in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Savolitinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Lung cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 13 Apr 2018 Status changed from active, no longer recruiting to completed.
- 14 Feb 2018 Planned end date changed from 27 Feb 2018 to 16 Mar 2018.
- 14 Feb 2018 Planned primary completion date changed from 27 Feb 2018 to 16 Mar 2018.